TITLE

FDA Actions

AUTHOR(S)
Elliott, William T.
PUB. DATE
January 2009
SOURCE
Travel Medicine Advisor;Jan2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of the U.S. Food & Drug Administration (FDA) to approve fesoterodine fumarate for the treatment of overactive bladder. The drug's effect includes relaxing the smooth muscle of the bladder which reduces the frequency of urination, the urge to urinate and sudden urinary incontinence. It is manufactured by Schwartz Pharma and will be marketed as Toviaz.
ACCESSION #
35903676

 

Related Articles

  • FDA Actions.  // Neurology Alert;Jan2009 Pharmacology Watch, p2 

    The article reports on the approval of fesoterodine fumarate for the treatment of overactive bladder by the U.S. Food and Drug Administration (FDA). Manufactured by SchwartzPharma, the drug relaxes smooth muscle of the bladder reducing urinary frequency, urge to urinate, and sudden urinary...

  • FDA Actions.  // Clinical Oncology Alert;Jan2009 Pharmacology Watch, p2 

    The article reports on the decision of the U.S. Food & Drug Administration to approve fesoterodine fumarate for the treatment of overactive bladder. The drug's effect is that it relaxes the smooth muscle of the bladder, thus reducing urinary frequency, urge to urinate and sudden urinary...

  • FDA Actions.  // Infectious Disease Alert;Jan2009 Pharmacology Watch, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved fesoterodine fumarate for the treatment of overactive bladder in January 2009. Manufactured by Schwartz Pharma, the drug will be marketed under the brand name Toviaz. It states that the drug reduces urinary...

  • FDA approves first Parkinson's patch. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;6/15/2007, Vol. 64 Issue 12, p1244 

    The article reports on the approval of the market­ing of Neupro, a transdermal system by Schwarz Pharma that continuously delivers rotigotine, a "non-ergolinic" dopamine-receptor agonist by the Food and Drug Administration (FDA) in the U.S. Dizziness, nausea, vomiting, drowsiness, insomnia,...

  • Schwarz launch orally dissolving Parkinson's drug.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p9 

    Reports that the U.S. division of pharmaceutical firm Schwarz has launched Parkinson's treatment Parcopa. Description of the drug as a carbidopa-levodopa formulation that dissolves rapidly on the tongue; Approval of Parcopa by the U.S. Food and Drug Administration on August 27, 2004; Treatment...

  • Schwarz Pharma: Neupro to improve patient convenience in Parkinson's.  // PharmaWatch: CNS;Jun2007, Vol. 6 Issue 6, p5 

    The article reports on the approval of Schwarz Pharma's Neupro by the U.S. Food and Drug Administration. The drug is a transdermal patch formulation of the dopamine agonist rotigotine for the treatment of early-stage Parkinson's disease. Neupro is designed for once-daily application, making the...

  • BOTOX for bladder control. LOTEMPIO, SUSAN M. // New Mobility;Oct2013, Vol. 24 Issue 241, p14 

    The article offers the author's insight on her experience of Botox injections to regain control of her bladder. She relates her experience of work-related stress due to urinary incontinence and its impact on the quality of her life and those who have the disorder. She discusses how the Botox...

  • Patch offers new option for early Parkinson's. Belden, Heidi // Drug Topics;6/4/2007, Vol. 151 Issue 11, p12 

    The article reports on the approval of rotigotine transdermal system, Neupro, from Schwarz Pharma SpAbio by the U.S. Food and Drug Administration (FDA) for the treatment of the symptoms of early Parkinson's disease. The drug is a once-daily patch that activates dopamine receptors within the...

  • Toviaz approved to treat overactive bladders. Fernandez, Veronica // Drug Topics;3/1/2009, Vol. 153 Issue 3, pH12 

    The article discusses the approval of the Toviaz, an extended-release tablets for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency by the Food and Drug Administration in the U.S. It states that its approval was based on 12-week studies which...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics